Prospective randomized human trials, crossover pharmacokinetic studies, and ClinicalTrials.gov interventional readouts with direct participant sample sizes (N). Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
In hypertensive patients with ECG left ventricular hypertrophy with existing or new irregular heartbeat (AFib), digoxin use is not associated with a significantly increased risk of all-cause mortality after adjusting for other...
Pioglitazone added to metformin and alogliptin significantly improved blood sugar control in patients with type 2 diabetes, and was non-inferior to dapagliflozin.
T80/A5/H12.5 therapy was clinically and statistically superior to T80/H12.5 therapy.
In this 12-week study, Sancai powder could significantly reduce hemoglobin A1c, FPG and 2hPG levels, improved beta-cell function and insulin resistance of the T2DM inadequately controlled with metformin.
Compared with statin single-drug treatment, combination therapy with ezetimibe further reduced LDL-C levels.
The effect of escitalopram on PSD may be more prominent in patients with particular depressive symptoms and stroke lesion locations, suggesting the need for tailored treatment strategies.
This study shows that both transdermal and oral estradiol are effective in relieving menopausal symptoms, with little difference in treatment real-world benefits and safety.
These findings suggest that the change in PRO and P/E2 may influence negative mood factors differently in men and women who smoke.
Within three months, both combinations are comparably effective in improving BPH related LUTS.
S-equol supplement improved mood-related symptoms in perimenopausal/postmenopausal equol nonproducers.
The differences found between acitretin and etretinate may be related to higher maximum plasma concentrations of acitretin.
Daily administration of tadalafil at 5 mg can effectively improve the IPSS sub-item scores in the urinary storage symptoms and IIEF-5 scores, with a persistent effect after withdrawal similar to that of its combination with...
The CAN-BIND cohort included 125 participants (mean [SD] age, 36.4 [13.0] years; 78 [62.4%] women), and the EMBARC sertraline treatment group included 105 participants (mean [SD] age, 38.4 [13.8] years; 72 [68.6%] women).
Telmisartan/rosuvastatin SPC therapy was more effective in lowering central BP compared with the telmisartan single-drug treatment.
PedPRM was efficacious and safe for treatment of trouble sleeping in children and adolescents with ASD with/without ADHD and NGD.
For the 366 participants (PBO, n = 124; PIO15, n = 118; PIO30, n = 124), the mean age was 55.6 years and mean duration of diabetes was 8.7 years, with a baseline HbA 1c of 7.9%.
Connectivity of the cognitive control circuit during response inhibition selectively and differentially predicts antidepressant treatment response and correlates with symptom improvement.
These findings do not support the hypothesis that elevated baseline inflammatory markers predict poor response to sertraline in patients with CHD and major depression.
The findings from this study indicate that combining CBT-I with PAP is superior to PAP alone on trouble sleeping outcomes but does not significantly improve staying on track with medication to PAP.
Compared with the S group, patients in the S+EX group displayed significantly greater improvements of the affective symptom dimension (total effect size = 0.79) with largest changes in the first 4 weeks and last 12 weeks.
The combination of PE and sertraline could improve the management of LLMD, especially when customized for individuals with specific clinical features.
Physical exercise may be a safe and effective augmentation to antidepressant therapy in late-life major depression.
Blonanserin can effectively relieve the symptoms of schizophrenia and improve the quality of life of first-episode schizophrenia patients who have failed to respond to Risperidone monotherapy in the early stage.
No serious treatment-related adverse events were recorded.ConclusionsAdjunctive neodymium-doped yttrium aluminum garnet laser therapy was associated with greater short-term improvement in periodontal clinical outcomes than conventional nonsurgical periodontal therapy alone.
A short-course applied to the skin diclofenac epolamine patch, combined with rehabilitation training, effectively alleviates pain, accelerates functional recovery, and is safe for treating moderate hamstring strain, supporting...
Network analysis revealed a pre-treatment relationship between a HSA and decreased phonemic VF among depressed patients, which was no longer present after 8 weeks of antidepressant treatment.
GLP-1R rs10305420 polymorphism can explain some of the inter-individual differences in glycemic response to liraglutide in a population of Iranian people with T2DM.
Results of the study highlight that vildagliptin and empagliflozin have a significant beneficial effect in reducing HbA1c, fasting blood glucose, systolic blood pressure, and weight of participants.
These results provide further validation of the sleep-enhancing effects of 28-days of saffron supplementation in adults with unsatisfactory sleep.
In patients with HbA1c ≥10% treatment with GLP1RA plus basal insulin, compared with basal-bolus insulin, resulted in better glycaemic control and body weight, lower insulin dosage and hypoglycaemia, and improved quality of life.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
